Drug Trial Radar · NCT05611801
A Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia B
Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
100
Planned (sponsor's estimate)
Start
Dec 9, 2022
Primary completion
Sep 10, 2028
Study completion Sep 10, 2028
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Nov 10, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 1 year, up to 17 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called marstacimab) for the potential treatment of hemophilia in pediatric patients. This study will enroll pediatric participants from ages 1 to 17 years in a sequential manner. The study opened the enrollment to adolescent participants aged 12 to 17 years first. Then children aged 6 to 11 years erere permitted to enroll. Lastly, children aged 1 to 5 years are permitted to enroll. This study will enroll male participants who: * have severe Hemophilia A or moderately severe to severe Hemophilia B (with or without inhibitors) * have accurate historical records documenting all factor VIII, factor IX, or bypass agent infusions and hemophilia bleed events for at least 1 year prior to entering the study for participants from 6 to 17 years of age, and at least 3 months prior to entering the study for participants from 1 to 5 years of age * if a non-inhibitor patient, must be on a stable routine prophylaxis regimen with factor VIII or factor IX replacement products for at least 12 months prior to study entry for participants from 6 to 17 years of age, and least 3 months for participants aged from 1 to 5 years of age * if an inhibitor patient, must be on an on-demand bypass treatment regimen during the 12 months prior to study entry for participants from 6 to 17 years of age, and during the 3 months prior to study entry for participants aged from 1 to 5 years of age All participants in this study will receive marstacimab to use prophylactically. Marstacimab will be given once a week as a subcutaneous (under the skin) shot. The first dose of marstacimab will be given at the study site by the study site staff. During the 12-month treatment period, weekly doses of marstacimab can be given at home, or if preferred, the doses may be given by the study site staff. To help us determine if the study medicine is safe and effective, we will compare participant experiences when they are taking the study medicine to a historical period when they were not. Researchers want to see if the study medicine works to prevent the bleeding episodes commonly experienced by patients with Hemophilia. Participants will be in this study for about 14 months (approximately 1 month in a Screening period, 12 months receiving treatment, and 1 month in a follow-up period) during which they will visit the study site at least 10 times. If preferred, and if local regulations allow it, 2 of the study visits can be completed at the participant's home instead of at the study site. There will also be 6 scheduled telephone calls approximately every 2 months.
Conditions
- Hemophilia A
- Hemophilia B
Interventions
marstacimabDrug
marstacimab
Primary outcomes
What the sponsor says the trial is designed to measure.
- Annualized bleeding rate (ABR) of treated bleeding eventsTime frame: Baseline (up to 12 months prior to informed consent) to the end of the 12-month treatment period
- Incidence of adverse events and serious adverse eventsTime frame: Screening through end of follow-up period (approximately 14 months)
- Incidence and severity of thrombotic eventsTime frame: Baseline to end of 12-month treatment period
- Incidence and severity of thrombotic microangiopathyTime frame: Baseline to end of 12-month treatment period
- Incidence and severity of disseminated intravascular coagulation/consumption coagulopathy eventsTime frame: Baseline to end of 12-month treatment period
- Immunogenicity (incidence of ADA and clinically significant persistent NAb against marstacimab)Time frame: Baseline to end of 12-month treatment period
- Incidence and severity of injection site reactionTime frame: Baseline to end of 12-month treatment period
- Incidence of severe hypersensitivity and anaphylactic reactionsTime frame: Baseline to end of 12-month treatment period
Locations
62 sites in 22 countries. Site status is shown where the registry gives one.
Intermountain - Primary Children's Hospital
Salt Lake City, Utah · Recruiting
Arbesu Hematología
Mendoza, Argentina · Recruiting
Murdoch Children's Research Institute
Parkville, Australia · Recruiting
Medizinische Universität Wien
Vienna, State of Vienna, Austria · Recruiting
Centro Estadual de Hemoterapia e Hematologia Marcos Daniel Santos - HEMOES
Maruípe, Vitória, Brazil · Active not recruiting
Stollery Children's Hospital
Edmonton, Alberta, Canada · Active not recruiting
Hamilton Health Sciences - McMaster University/McMaster Children's Hospital
Hamilton, Ontario, Canada · Active not recruiting
Beijing Children's hospital, Capital Medical University
Beijing, Beijing Municipality, China · Recruiting
Southern Medical University Nanfang Hospital
Guangzhou, Guangdong, China · Active not recruiting
The Affiliated Hospital of Guizhou Medical University
Guiyang, Guizhou, China · Active not recruiting
Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology
Wuhan, Hubei, China · Recruiting
Tongji Hospital of Tongji Medical College of HUST/Pediatric Hematology Department Pharmacy
Wuhan, Hubei, China · Recruiting
Jiangxi Provincial People's Hospital
Nanchang, Jiangxi, China · Active not recruiting
Institute of hematology&blood disease hospital
Tianjin, Tianjin Municipality, China · Recruiting
Fakultni nemocnice Brno
Brno, Czechia · Recruiting
Fakultni nemocnice v Motole
Prague, Czechia · Recruiting
Detska nemocnice FN Brno
Brno, Brno-město, Czechia · Recruiting
Aarhus Universitetshospital, Skejby
Aarhus N, Denmark · Recruiting
Aarhus University
Aarhus N, Denmark · Recruiting
Rigshospitalet
Copenhagen, Capital Region, Denmark · Recruiting
Charité Campus Virchow-Klinikum
Berlin, Germany · Active not recruiting
Nirmal Hospital Pvt Ltd.
Surat, Gujarat, India · Recruiting
K. J. Somaiya Hospital and Research Centre, Somaiya Ayurvihar Complex
Mumbai, Maharashtra, India · Recruiting
Nil Ratan Sircar Medical College and Hospital
Kolkata, West Bengal, India · Recruiting
Sheba Medical Center
Ramat Gan, Central District, Israel · Recruiting
Azienda Ospedaliero Universitaria di Parma
Parma, Italy · Recruiting
Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino
Torino, Italy · Recruiting
IRCCS Istituto Giannina Gaslini
Genoa, Liguria, Italy · Recruiting
Istituto Clinico Humanitas - Humanitas Mirasole SPA
Rozzano, Milan, Italy · Recruiting
Ospedale Pediatrico Bambino Gesù IRCCS
Rome, ROMA, Italy · Recruiting
Saga University Hospital
Saga, Japan · Active not recruiting
Hyogo prefectural Kobe Children's Hospital
Kobe, Hyōgo, Japan · Recruiting
Nagano Children's Hospital
Azumino, Nagano, Japan · Active not recruiting
Nara Medical University Hospital
Kashihara, Nara, Japan · Recruiting
Saitama Prefectural Children's Medical Center
Saitama-shi, Saitama, Japan · Recruiting
King Fahad Specialist Hospital
Dammam, Saudi Arabia · Active not recruiting
Detska fakultna nemocnica Kosice
Košice, Slovakia · Recruiting
Univerzitna nemocnica Martin
Martin, Slovakia · Recruiting
Worthwhile Clinical Trials
Benoni, Gauteng, South Africa · Active not recruiting
Charlotte Maxeke Johannesburg Academic Hospital
Johannesburg, Gauteng, South Africa · Active not recruiting
Showing 40 of 62 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.